Sirolimus
- PDF / 169,020 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 79 Downloads / 157 Views
1 S
Erysipelas: case report In a single-centre, retrospective study of 9 patients with severe hidradenitis suppurativa (HS) treated at a hospital in France between January 2014 and April 2020, a patient [age and sex not stated] was described, who developed erysipelas during treatment with oral sirolimus at a progressively increased dosage for severe HS [dosage received and time to reaction onset not stated]. Concomitantly, the patient received unspecified tumour necrosis alpha inhibitor for HS, and the patient had previously received rifampicin, clindamycin and infliximab [outcome of ADR not stated]. Bettuzzi T, et al. Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa. Journal of the American 803519575 Academy of Dermatology 83: 1441-1444, No. 5, Nov 2020. Available from: URL: http://doi.org/10.1016/j.jaad.2020.06.042
0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Dec 2020 No. 1833
Data Loading...
